Jill M. Quigley - 09 Sep 2024 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role
Director
Signature
/s/ David Strauss as Attorney-in-Fact for Jill M. Quigley
Issuer symbol
TERN
Transactions as of
09 Sep 2024
Net transactions value
-$140,982
Form type
4
Filing time
11 Sep 2024, 18:00:22 UTC
Previous filing
05 Aug 2024
Next filing
06 Jan 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TERN Common Stock Options Exercise $31,368 +17,235 +115% $1.82 32,235 09 Sep 2024 Direct F1
transaction TERN Common Stock Sale $172,350 -17,235 -53% $10.00 15,000 09 Sep 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TERN Stock Option (Right to Buy) Options Exercise $0 -17,235 -100% $0.000000 0 09 Sep 2024 Common Stock 17,235 $1.82 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024.
F2 The option vested in full immediately prior to the Annual Meeting following the date of grant.